

BioEquin FT suspension for injection for horses

Authorised

- Influenza A virus, subtype H3N8, strain A/equine/Brno/08, Inactivated
- Clostridium tetani, toxoid
- Influenza A virus, subtype H3N8, strain A/equine/Limerick/2010, Inactivated

Product identification

Medicine name:

BioEquin FT suspension for injection for horses

Active substance:

Influenza A virus, subtype H3N8, strain A/equine/Brno/08, Inactivated

Clostridium tetani, toxoid

Influenza A virus, subtype H3N8, strain A/equine/Limerick/2010, Inactivated

Target species:

Horse

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Influenza A virus, subtype H3N8, strain A/equine/Brno/08, Inactivated

5.00 log₂ haemagglutination inhibiting unit(s) / 1.00 Dose

Clostridium tetani, toxoid

30.00 international unit(s) / 1.00 Dose

Influenza A virus, subtype H3N8, strain A/equine/Limerick/2010, Inactivated

5.00 log₂ haemagglutination inhibiting unit(s) / 1.00 Dose

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Horse

- Milk. 0 hour

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI05AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Bulgaria

Package description:

glass vial 2 x 1.0 dose

glass vial 5 x 1.0 dose

glass vial 10 x 1.0 dose

glass vial 1 x 5.0 dose

glass vial 10 x 5.0 dose

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Bioveta a.s.

Marketing authorisation date:

28/05/2025

Manufacturing sites for batch release:

Bioveta a.s.

Responsible authority:

Bulgarian Food Safety Authority

Authorisation number:

0022-3299

Date of authorisation status change:

28/05/2025

Reference member state:

Czechia

Procedure number:

CZ/V/0201/001

Concerned member states:

Austria Belgium Bulgaria Denmark Finland France Germany Ireland Italy
Netherlands Norway Poland Portugal Romania Slovakia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 13/03/2026

[Download](#)

Package Leaflet

English (PDF)

Published on: 13/03/2026

[Download](#)

Labelling

English (PDF)

Published on: 13/03/2026

[Download](#)

eu-puar-czv0201001-mr-bioequin_ft-en.pdf